Co-expression network analysis of differentially expressed genes associated with metastasis in prolactin pituitary tumors

Molecular Medicine Reports

Volumn 10, Issue 1, 2014, Pages 113-118

  Zhang, Wei ^a   Zang, Zhenle ^a   Song, Yechun ^a   Yang, Hui ^a   Yin, Qing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Co expression network; Differentially expressed genes; Prolactin pituitary tumor; Tumor metastasis

Indexed keywords

CHROMOGRANIN B; CYCLIC AMP; GLUCOCORTICOID; GLUCOSE TRANSPORTER; KARYOPHERIN; MEMBRANE PROTEIN; PROLACTIN; TENEURIN TRANSMEMBRANE PROTEIN 1; UNCLASSIFIED DRUG; CHGB PROTEIN, HUMAN; SLC2A11 PROTEIN, HUMAN;

ARTICLE; BIOINFORMATICS; CELL CYCLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; HUMAN; HYPOPHYSIS TUMOR; METASTASIS; TUMOR GROWTH; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; METABOLISM; PATHOLOGY; PROLACTINOMA;

CHROMOGRANIN B; CLUSTER ANALYSIS; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROLACTINOMA;

EID: 84901441429     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2152     Document Type: Article

References (35)

1. Mindermann T and Wilson CB: Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41: 359-364, 1994. (Pubitemid 24278331)
2. Dessimoz C, Browaeys P, Maeder P, et al: Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma. Front Neuroendocrin (Lausanne) 2: 116, 2011.
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA and Beckers A: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769-4775, 2006. (Pubitemid 44917305)
4. Ma W, Ikeda H and Yoshimoto T: Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95: 258-266, 2002. (Pubitemid 34787590)
5. Ahtiainen P, Sharp V, Rulli SB, et al: Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocr Relat Cancer 17: 611-621, 2010.
6. Ali S, Miller KK and Freudenreich O: Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 51: 370-376, 2010.
7. Gillam MP, Molitch ME, Lombardi G and Colao A: Advances in the treatment of prolactinomas. Endocr Rev 27: 485-534, 2006. (Pubitemid 44213229)
8. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y and Melmed S: Heregulin regulates prolactinoma gene expression. Cancer Res 69: 4209-4216, 2009.
9. Leriche VK, Asa SL and Ezzat S: Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 81: 656-662, 1996. (Pubitemid 26055681)
10. Roncaroli F, Nosé V, Scheithauer BW, et al: Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. J Neurosurg 99: 402- 408, 2003.
11. Onguru O, Scheithauer BW, Kovacs K, et al: Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 17: 772-780, 2004. (Pubitemid 38843359)
12. Zhang H, Berezov A, Wang Q, et al: ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058, 2007. (Pubitemid 47224766)
13. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996. (Pubitemid 26315047)
14. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG and Melmed S: Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 68: 6377-6386, 2008.
15. Wierinckx A, Roche M, Raverot G, et al: Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol 21: 533-543, 2011.
16. Toedling J, Sklyar O, Huber W, et al: Ringo - an R/Bioconductor package for analyzing ChIP- chip readouts. BMC Bioinformatics 8: 221, 2007.
17. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003. (Pubitemid 36181903)
18. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998. (Pubitemid 29003722)
19. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
20. Kanehisa M: The KEGG database. Novartis Found Symp 247: 91-103; discussion 119-128, 244-152, 2002.
21. Hulsegge I, Kommadath A and Smits MA: Globaltest and GOEAST: two different approaches for Gene Ontology analysis. BMC Proc 3 (Suppl 4): S10, 2009.
22. Becker RA, Chambers JM and Wilks AR. The New S Language: A Programming Environment for Data Analysis and Graphics. Vol 1. Chapman & Hall, London, 1988.
23. Melmed S: Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112: 1603-1618, 2003.
24. Casanueva FF, Molitch ME, Schlechte JA, et al: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65: 265-273, 2006. (Pubitemid 44079693)
25. Olafsdottir A and Schlechte J: Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2: 552-561, 2006. (Pubitemid 44536603)
26. Whitelaw BC, Dworakowska D, Thomas NW, et al: Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76: 877-886, 2012.
27. Ragel BT and Couldwell WT: Pituitary carcinoma: a review of the literature. Neurosurg Focus 16: E7, 2004.
28. Riva C, Leutner M, Capella C, et al: Different expression of chromogranin A and chromogranin B in various types of pituitary adenomas. Zentralbl Pathol 139: 165-170, 1993.
29. Jin L, Scheithauer BW, Young WF Jr, Davis DH, Klee GG and Lloyd RV: Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Am J Pathol 148: 2057-2066, 1996. (Pubitemid 26170528)
30. Louthan O: Chromogranin a in physiology and oncology. Folia Biol (Praha) 57: 173-181, 2011.
31. Golomb L, Bublik DR, Wilder S, et al: Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 45: 222-232, 2012.
32. Atasheva S, Fish A, Fornerod M and Frolova EI: Venezuelan equine Encephalitis virus capsid protein forms a tetrameric complex with CRM1 and importin alpha/ beta that obstructs nuclear pore complex function. J Virol 84: 4158-4171, 2010.
33. Doege H, Bocianski A, Scheepers A, et al: Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar-transport facilitator specifically expressed in heart and skeletal muscle. Biochem J 359: 443-449, 2001. (Pubitemid 32999791)
34. Kenzelmann D, Chiquet-Ehrismann R, Leachman NT and Tucker RP: Teneurin-1 is expressed in interconnected regions of the developing brain and is processed in vivo. BMC Dev Biol 8: 30, 2008.
35. Beckmann J, Vitobello A, Ferralli J, Kenzelmann Brož DK, Rijli FM and Chiquet-Ehrismann R: Human teneurin-1 is a direct target of the homeobox transcription factor EMX2 at a novel alternate promoter. BMC Dev Biol 11: 35, 2011.